About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AXSM · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
NCT07398417 · Fibromyalgia
AXS-14 (Esreboxetine), Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Recruiting620Mar 2028Registry ↗
Nov 6, 2026An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With…
NCT07773883 · ADHD
Solriamfetol
AXSM
Axsome Therapeutics, Inc.
Phase 3Enrolling by invitation300Dec 2027Registry ↗
Nov 6, 2026Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
NCT07766655 · Smoking Cessation
AXS-05 (dextromethorphan-bupropion), Bupropion
AXSM
Axsome Therapeutics, Inc.
Phase 3Recruiting705Dec 2027Registry ↗
Nov 6, 2026Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
NCT07717892 · ADHD
Solriamfetol Dose A, Solriamfetol Dose B
AXSM
Axsome Therapeutics, Inc.
Phase 3Recruiting468Jun 30, 2028Registry ↗
Nov 6, 2026Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
NCT07717879 · ADHD
Solriamfetol Dose A, Solriamfetol Dose B
AXSM
Axsome Therapeutics, Inc.
Phase 3Recruiting468Jun 30, 2028Registry ↗
Nov 6, 2026Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
NCT07637162 · Fibromyalgia
AXS-14 (esreboxetine)
AXSM
Axsome Therapeutics, Inc.
Phase 3Enrolling by invitation300May 2028Registry ↗
Nov 6, 2026A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating D…
NCT06878976 · Binge-Eating Disorder
Solriamfetol, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Enrolling by invitation236Dec 2027Registry ↗
Oct 13, 2026Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solria…
NCT07484217 · Major Depressive Disorder With Excessive Daytime Sleepiness…
Solriamfetol 150 MG, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Recruiting508Dec 2028Registry ↗
Oct 5, 2026SUNOSI® (Solriamfetol) Pregnancy Registry
NCT06413420 · Narcolepsy, Obstructive Sleep Apnea
Sunosi (solriamfetol), Other prescription wake-promoting me…
AXSM
Axsome Therapeutics, Inc.
—Recruiting1,731Sep 2029Registry ↗
Aug 13, 2026A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
NCT05557409 · Agitation in Patients With Dementia of the Alzheimer's Type…
AXS-05, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed408Nov 21, 2024Registry ↗
Jul 28, 2026Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433 · Binge-Eating Disorder
Solriamfetol 150 mg, Solriamfetol 300 mg
AXSM
Axsome Therapeutics, Inc.
Phase 3Recruiting450Dec 2026Registry ↗
Jul 24, 2026Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SU…
NCT06568367 · Excessive Sleepiness, Shift-work Disorder
Solriamfetol 150 mg, Solriamfetol 300 mg
AXSM
Axsome Therapeutics, Inc.
Phase 3Recruiting520Dec 2026Registry ↗
Jun 25, 2026An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzhe…
NCT06736509 · Agitation in Patients With Dementia of the Alzheimer's Type…
AXS-05 (dextromethorphan-bupropion)
AXSM
Axsome Therapeutics, Inc.
Phase 3Terminated139Feb 17, 2025Registry ↗
Jun 15, 2026Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
NCT03881852 · Narcolepsy, Cataplexy Narcolepsy
AXS-12 (Reboxetine), Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 2Completed21Nov 27, 2019Registry ↗
May 28, 2026A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
NCT05059223 · Narcolepsy, Cataplexy
AXS-12 (reboxetine), Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed90Mar 15, 2024Registry ↗
Feb 10, 2026A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
NCT05972044 · ADHD
Solriamfetol 150 mg, Solriamfetol 300 mg
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed516Feb 7, 2025Registry ↗
Jan 28, 2026Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
NCT04634669 · Treatment Resistant Depression, Major Depressive Disorder
AXS-05 (dextromethorphan-bupropion)
AXSM
Axsome Therapeutics, Inc.
Phase 2Terminated181Feb 18, 2022Registry ↗
Jan 28, 2026Initiating Early Control of Migraine Pain and Associated Symptoms
NCT04163185 · Migraine
AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed302Mar 16, 2020Registry ↗
Jan 26, 2026Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-control…
NCT04789174 · Excessive Daytime Sleepiness, Obstructive Sleep Apnea
Solriamfetol, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 4Completed59Sep 19, 2022Registry ↗
Jan 5, 2026Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
NCT06360419 · Major Depressive Disorder
Solriamfetol 300 mg, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed346Dec 31, 2024Registry ↗
Dec 8, 2025A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease…
NCT04947553 · Agitation in Patients With Dementia of the Alzheimer's Type…
AXS-05 (dextromethorphan-bupropion), Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed456Dec 3, 2024Registry ↗
Dec 2, 2025Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Re…
NCT05550207 · Migraine
AXS-07 (meloxicam-rizatriptan)
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed100Nov 27, 2024Registry ↗
Nov 13, 2025A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcole…
NCT05113745 · Narcolepsy, Cataplexy
AXS-12 (reboxetine), Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed68Nov 15, 2024Registry ↗
Jan 23, 2025A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depre…
NCT06223880 · Major Depressive Disorder
AXS-05, Bupropion
AXSM
Axsome Therapeutics, Inc.
Phase 4Recruiting350Mar 2026Registry ↗
Nov 29, 2023Assessing Clinical Outcomes in Alzheimer's Disease Agitation
NCT04797715 · Agitation in Patients With Dementia of the Alzheimer's Type…
AXS-05, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed178Nov 21, 2022Registry ↗
Oct 10, 2023Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
NCT04068051 · Migraine
AXS-07
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed706Sep 22, 2020Registry ↗
Sep 13, 2023Addressing Dementia Via Agitation-Centered Evaluation
NCT03226522 · Agitation in Patients With Dementia of the Alzheimer's Type…
AXS-05, Bupropion
AXSM
Axsome Therapeutics, Inc.
Phase 2/3Completed366Apr 17, 2020Registry ↗
Aug 24, 2023Maximizing Outcomes in Treating Acute Migraine
NCT03896009 · Migraine
AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed1,594Dec 10, 2019Registry ↗
Apr 14, 2023Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Ora…
NCT05008341 · Narcolepsy, Obstructive Sleep Apnea
Solriamfetol 150 mg Oral Tablet
AXSM
Axsome Therapeutics, Inc.
Phase 1Completed6Apr 15, 2022Registry ↗
Oct 12, 2022Open-Label Safety Study of AXS-05 in Subjects With Depression
NCT04039022 · Major Depressive Disorder, Treatment Resistant Depression
AXS-05 (dextromethorphan and bupropion) oral tablets
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed876Oct 23, 2020Registry ↗
Oct 12, 2022A Trial of AXS-05 in Patients With Major Depressive Disorder
NCT04019704 · Depression, Major Depressive Disorder
AXS-05, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed327Nov 26, 2019Registry ↗
Jul 12, 2022Mechanistic Evaluation of Response in TRD (MERIT)
NCT04608396 · Treatment Resistant Depression, Major Depressive Disorder
AXS-05, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 2Completed44Jul 30, 2021Registry ↗
Sep 24, 2021Assessing Symptomatic Clinical Episodes in Depression
NCT03595579 · Major Depressive Disorder
AXS-05, Bupropion
AXSM
Axsome Therapeutics, Inc.
Phase 2Completed97Jan 7, 2019Registry ↗
Jul 26, 2021An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
NCT04971291 · Major Depressive Disorder, Treatment Resistant Depression
AXS-05, Bupropion SR
AXSM
Axsome Therapeutics, Inc.
Phase 2Unknown312Jul 2021Registry ↗
Mar 24, 2021A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depr…
NCT02741791 · Treatment Resistant Major Depressive Disorder
AXS-05, Bupropion
AXSM
Axsome Therapeutics, Inc.
Phase 3Completed312Mar 20, 2020Registry ↗
Jan 10, 2019A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone M…
NCT02746068 · Osteoarthritis, Knee
AXS-02, Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Unknown346Dec 2020Registry ↗
Mar 23, 2018CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
NCT02504008 · Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
AXS-02 (oral zoledronate), Placebo
AXSM
Axsome Therapeutics, Inc.
Phase 3Unknown190Jan 2019Registry ↗

37 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:11 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances